TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The prevalence of obesity in children is reaching epidemic proportions. Excess adiposity is more than just a cosmetic problem, having substantial metabolic consequences. Insulin resistance, hyperinsulinemia, impaired glucose tolerance, and frank diabetes are often seen in obese children. In this study the prevalence of impaired glucose (carbohydrate) tolerance in lean children with a family history of diabetes and obese children with acanthosis nigricans with or without a family history of diabetes mellitus will be studied.


Options:
A: Arm Label: sorafenib group; Type: ACTIVE_COMPARATOR; Interventions: Drug: sorafenib | Arm Label: radioembolization group; Type: ACTIVE_COMPARATOR; Interventions: Drug: SIR-Sphere | Intervention Type: DRUG; Name: sorafenib; Assigned to Arm(s): sorafenib group | Intervention Type: DRUG; Name: SIR-Sphere; Assigned to Arm(s): radioembolization group
B: Arm Label: Sorafenib, Multikinase Inhibitor, Tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib tosylate | Arm Label: SIR-Spheres, Microspheres, Device; Type: ACTIVE_COMPARATOR; Interventions: Device: SIR-Spheres | Intervention Type: DEVICE; Name: SIR-Spheres; Assigned to Arm(s): SIR-Spheres, Microspheres, Device | Intervention Type: DRUG; Name: Sorafenib tosylate; Assigned to Arm(s): Sorafenib, Multikinase Inhibitor, Tablet
C: Intervention Type: DEVICE; Name: Yttrium-90 microspheres (Therasphere MDS Nordion); Assigned to Arm(s): N/A
D: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Correction of Myopia Evaluation Trial (COMET)
Brief Summary: To evaluate whether progressive addition lenses (PALs) slow the rate of progression of juvenile-onset myopia (nearsightedness) when compared with single vision lenses, as measured by cycloplegic autorefraction. An additional outcome measure is axial length, as measured by A-scan ultrasonography.

To describe the natural history of juvenile-onset myopia in a group of children receiving conventional treatment (single vision lenses).


Options:
A: Intervention Type: DRUG; Name: Atropine Eye drops; Assigned to Arm(s): N/A
B: Arm Label: Progressive Addition Lenses (PALs); Type: EXPERIMENTAL; Interventions: Other: Progressive Addition Lenses | Arm Label: Single Vision Lenses; Type: ACTIVE_COMPARATOR; Interventions: Other: single vision lenses | Intervention Type: OTHER; Name: Progressive Addition Lenses; Assigned to Arm(s): Progressive Addition Lenses (PALs) | Intervention Type: OTHER; Name: single vision lenses; Assigned to Arm(s): Single Vision Lenses
C: Arm Label: PAL; Type: EXPERIMENTAL; Interventions: Device: progressive addition spectacle lens (bifocal) | Arm Label: SVL; Type: ACTIVE_COMPARATOR; Interventions: Device: Single Vision Lenses (SVLs) | Intervention Type: DEVICE; Name: progressive addition spectacle lens (bifocal); Assigned to Arm(s): PAL | Intervention Type: DEVICE; Name: Single Vision Lenses (SVLs); Assigned to Arm(s): SVL
D: Arm Label: Orthokeratology lenses; Type: EXPERIMENTAL; Interventions: Device: Orthokeratology lenses | Arm Label: Single-vision spectacle lenses; Type: OTHER; Interventions: Device: Single-vision spectacle lenses | Intervention Type: DEVICE; Name: Orthokeratology lenses; Assigned to Arm(s): Orthokeratology lenses | Intervention Type: DEVICE; Name: Single-vision spectacle lenses; Assigned to Arm(s): Single-vision spectacle lenses

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Correction of Myopia Evaluation Trial (COMET)
Brief Summary: To evaluate whether progressive addition lenses (PALs) slow the rate of progression of juvenile-onset myopia (nearsightedness) when compared with single vision lenses, as measured by cycloplegic autorefraction. An additional outcome measure is axial length, as measured by A-scan ultrasonography.

To describe the natural history of juvenile-onset myopia in a group of children receiving conventional treatment (single vision lenses).


Options:
A: Intervention Type: DEVICE; Name: Polymethyl Methacrylate-Silicone Contact Lenses; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Polymethyl Methacrylate Contact Lenses; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: 0.25 % atropine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 0.5 % atropine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: 0.25 % atropine+auricular acupoints; Assigned to Arm(s): N/A
C: Arm Label: Progressive Addition Lenses (PALs); Type: EXPERIMENTAL; Interventions: Other: Progressive Addition Lenses | Arm Label: Single Vision Lenses; Type: ACTIVE_COMPARATOR; Interventions: Other: single vision lenses | Intervention Type: OTHER; Name: Progressive Addition Lenses; Assigned to Arm(s): Progressive Addition Lenses (PALs) | Intervention Type: OTHER; Name: single vision lenses; Assigned to Arm(s): Single Vision Lenses
D: Arm Label: Orthokeratology lenses; Type: EXPERIMENTAL; Interventions: Device: Orthokeratology lenses | Arm Label: Single-vision spectacle lenses; Type: OTHER; Interventions: Device: Single-vision spectacle lenses | Intervention Type: DEVICE; Name: Orthokeratology lenses; Assigned to Arm(s): Orthokeratology lenses | Intervention Type: DEVICE; Name: Single-vision spectacle lenses; Assigned to Arm(s): Single-vision spectacle lenses

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate the relative efficacy of orthokeratology, primarily by assessment of changes in central corneal thickness, astigmatism, visual acuity, endothelial cell density, and corneal curvature.

To evaluate the relative safety of orthokeratology, primarily by assessment of changes in central corneal thickness, astigmatism, visual acuity, endothelial cell density, induced corneal edema, and epithelial staining.

To assess the duration of any orthokeratology treatment effect.

To study the mechanisms by which refractive error and visual acuity changes occur, in particular the contribution that comes from changes in corneal curvature and shape.

To determine whether there were any predisposing ocular factors that could be used to predict which subjects will experience changes or complications.


Options:
A: Intervention Type: DEVICE; Name: Bifocal Spectacle Lenses; Assigned to Arm(s): N/A
B: Intervention Type: DEVICE; Name: Polymethyl Methacrylate-Silicone Contact Lenses; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Polymethyl Methacrylate Contact Lenses; Assigned to Arm(s): N/A
C: Arm Label: Single-vision glasses; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Orthokeratology with normal compression factor; Type: SHAM_COMPARATOR; Interventions: Device: Orthokeratology | Arm Label: Orthokeratology with increased compression factor; Type: ACTIVE_COMPARATOR; Interventions: Device: Orthokeratology | Intervention Type: DEVICE; Name: Orthokeratology; Assigned to Arm(s): Orthokeratology with increased compression factor, Orthokeratology with normal compression factor
D: Intervention Type: DRUG; Name: 0.25 % atropine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 0.5 % atropine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: 0.25 % atropine+auricular acupoints; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To test the hypothesis that correction with bifocal spectacle lenses rather than single-vision lenses will slow the progression of myopia in children with near-point esophoria. The primary outcome variable is cycloplegic refraction as measured with an automated refractor. Axial length is measured with ultrasound in order to test the corollary hypothesis that use of bifocals will slow ocular growth in these myopic children. We will also examine the amount of close work performed by subjects and the degree of parental myopia as factors that may influence myopia progression.


Options:
A: Intervention Type: DEVICE; Name: Bifocal Spectacle Lenses; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: 7-methylxanthine; Assigned to Arm(s): N/A
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Outdoor activity; Type: EXPERIMENTAL; Interventions: Behavioral: Outdoor activity | Intervention Type: BEHAVIORAL; Name: Outdoor activity; Assigned to Arm(s): Outdoor activity
D: Arm Label: Bifocal spectacles; Type: ACTIVE_COMPARATOR; Interventions: Device: Bifocal spectacles | Arm Label: Prismatic bifocals; Type: ACTIVE_COMPARATOR; Interventions: Device: Prismatic bifocal spectacles | Arm Label: Single vision spectacles; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bifocal spectacles; Assigned to Arm(s): Bifocal spectacles | Intervention Type: DEVICE; Name: Prismatic bifocal spectacles; Assigned to Arm(s): Prismatic bifocals

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Submacular Surgery Trials (SST)
Brief Summary: To determine whether surgical removal of subfoveal choroidal neovascularization (CNV) and associated hemorrhage in patients with age-related macular degeneration (AMD), the ocular histoplasmosis syndrome (OHS), or idiopathic CNV stabilizes or improves vision more often than observation.

To determine how surgical removal compared to observation of subfoveal CNV due to AMD, OHS, or idiopathic causes changes the patient's perception of health- and vision-related "quality of life," as measured by telephone interview using the Medical Outcomes Survey Short Form-36 (MOS SF-36) instrument, the Hospital Anxiety and Depression Scale, and the National Eye Institute Visual Function Questionnaire (NEI VFQ-25).

To determine whether randomized trials of surgery are warranted for patients with subfoveal CNV associated with age-related macular degeneration not suitable for laser treatment.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: oseltamivir + zanamivir | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oseltamivir + zanamivir's placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: oseltamivir's placebo + zanamivir | Intervention Type: DRUG; Name: oseltamivir + zanamivir; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: oseltamivir + zanamivir's placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: oseltamivir's placebo + zanamivir; Assigned to Arm(s): 3
B: Intervention Type: PROCEDURE; Name: Subfoveal Choroidal Neovascularization Removal; Assigned to Arm(s): N/A
C: Arm Label: Pegcetacoplan 15 mg/100 µL Monthly for 12 months; Type: EXPERIMENTAL; Interventions: Drug: Pegcetacoplan | Arm Label: Pegcetacoplan 15 mg/100 µL EOM for 12 months; Type: EXPERIMENTAL; Interventions: Drug: Pegcetacoplan | Arm Label: Sham Monthly for 12 months; Type: SHAM_COMPARATOR; Interventions: Other: Sham Procedure | Arm Label: Sham EOM for 12 months; Type: SHAM_COMPARATOR; Interventions: Other: Sham Procedure | Intervention Type: DRUG; Name: Pegcetacoplan; Assigned to Arm(s): Pegcetacoplan 15 mg/100 µL EOM for 12 months, Pegcetacoplan 15 mg/100 µL Monthly for 12 months | Intervention Type: OTHER; Name: Sham Procedure; Assigned to Arm(s): Sham EOM for 12 months, Sham Monthly for 12 months
D: Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Eculizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Submacular Surgery Trials (SST)
Brief Summary: To determine whether surgical removal of subfoveal choroidal neovascularization (CNV) and associated hemorrhage in patients with age-related macular degeneration (AMD), the ocular histoplasmosis syndrome (OHS), or idiopathic CNV stabilizes or improves vision more often than observation.

To determine how surgical removal compared to observation of subfoveal CNV due to AMD, OHS, or idiopathic causes changes the patient's perception of health- and vision-related "quality of life," as measured by telephone interview using the Medical Outcomes Survey Short Form-36 (MOS SF-36) instrument, the Hospital Anxiety and Depression Scale, and the National Eye Institute Visual Function Questionnaire (NEI VFQ-25).

To determine whether randomized trials of surgery are warranted for patients with subfoveal CNV associated with age-related macular degeneration not suitable for laser treatment.


Options:
A: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: Subfoveal Choroidal Neovascularization Removal; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Submacular Surgery Trials (SST)
Brief Summary: To determine whether surgical removal of subfoveal choroidal neovascularization (CNV) and associated hemorrhage in patients with age-related macular degeneration (AMD), the ocular histoplasmosis syndrome (OHS), or idiopathic CNV stabilizes or improves vision more often than observation.

To determine how surgical removal compared to observation of subfoveal CNV due to AMD, OHS, or idiopathic causes changes the patient's perception of health- and vision-related "quality of life," as measured by telephone interview using the Medical Outcomes Survey Short Form-36 (MOS SF-36) instrument, the Hospital Anxiety and Depression Scale, and the National Eye Institute Visual Function Questionnaire (NEI VFQ-25).

To determine whether randomized trials of surgery are warranted for patients with subfoveal CNV associated with age-related macular degeneration not suitable for laser treatment.


Options:
A: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
B: Arm Label: bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): bevacizumab
C: Intervention Type: PROCEDURE; Name: Subfoveal Choroidal Neovascularization Removal; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To determine whether 50 mg of beta-carotene taken every other day reduces the risk of developing age-related macular degeneration (AMD) among male U.S. physicians who were aged 40 to 84 in 1982.

To investigate the possible relationship of AMD with other antioxidants, including selenium and vitamins A, C, and E.

To identify potential risk factors for development of AMD. Possible risk factors include height, systemic hypertension, cardiovascular disease, blood cholesterol, cigarette smoking, iris and skin color, sunlight exposure, body mass index, diabetes, and alcohol intake.


Options:
A: Arm Label: Vitamin E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin E | Arm Label: Vitamin C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin C | Arm Label: Multivitamin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin | Arm Label: Beta-carotene; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beta-carotene | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): Vitamin E | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin C; Assigned to Arm(s): Vitamin C | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin; Assigned to Arm(s): Multivitamin | Intervention Type: DIETARY_SUPPLEMENT; Name: Beta-carotene; Assigned to Arm(s): Beta-carotene
B: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Beta-Carotene; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin and mineral supplement, Drug: Escherichia coli Endotoxin (LPS), Drug: 100% O2, Drug: nitroglycerin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Escherichia coli Endotoxin (LPS), Drug: 100% O2, Drug: nitroglycerin | Intervention Type: DRUG; Name: vitamin and mineral supplement; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Escherichia coli Endotoxin (LPS); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: 100% O2; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: nitroglycerin; Assigned to Arm(s): 1, 2
D: Arm Label: OT-551 antioxidant eye drop; Type: EXPERIMENTAL; Interventions: Drug: OT-551 antioxidant eye drop | Intervention Type: DRUG; Name: OT-551 antioxidant eye drop; Assigned to Arm(s): OT-551 antioxidant eye drop

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Amblyopia Treatment Study: Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia
Brief Summary: * To determine whether the success rate with drug treatment (atropine) of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy
* To develop more precise estimates of the success rates of amblyopia treatment
* To identify factors that may be associated with successful treatment of amblyopia
* To collect data on the course of treated amblyopia to provide more precise estimates of treatment effects than are now available

Extended Follow up of Study Patients

* Primary: To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years.
* Secondary: To determine whether the long-term visual acuity outcome at age 10 years and at age 15 years differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care


Options:
A: Intervention Type: DEVICE; Name: 6 hours occlusion by patching; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: 12 hours occlusion by patching; Assigned to Arm(s): N/A
B: Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Eye Patch; Assigned to Arm(s): Patching
C: Arm Label: patching (occlusion therapy); Type: ACTIVE_COMPARATOR; Interventions: Other: patching | Arm Label: binocular games; Type: EXPERIMENTAL; Interventions: Other: binocular games | Intervention Type: OTHER; Name: patching; Assigned to Arm(s): patching (occlusion therapy) | Intervention Type: OTHER; Name: binocular games; Assigned to Arm(s): binocular games
D: Arm Label: Binocular Treatment; Type: EXPERIMENTAL; Interventions: Device: iPad® | Arm Label: Patching Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Patching 2 hours per day, 7 days per week | Intervention Type: DEVICE; Name: iPad®; Assigned to Arm(s): Binocular Treatment | Intervention Type: OTHER; Name: Patching 2 hours per day, 7 days per week; Assigned to Arm(s): Patching Treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Amblyopia Treatment Study: Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia
Brief Summary: * To determine whether the success rate with drug treatment (atropine) of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy
* To develop more precise estimates of the success rates of amblyopia treatment
* To identify factors that may be associated with successful treatment of amblyopia
* To collect data on the course of treated amblyopia to provide more precise estimates of treatment effects than are now available

Extended Follow up of Study Patients

* Primary: To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years.
* Secondary: To determine whether the long-term visual acuity outcome at age 10 years and at age 15 years differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care


Options:
A: Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Eye Patch; Assigned to Arm(s): Patching
B: Intervention Type: DEVICE; Name: 6 hours occlusion by patching; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: 12 hours occlusion by patching; Assigned to Arm(s): N/A
C: Arm Label: Near activities; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch, Procedure: Near activities | Arm Label: Distance activities; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch, Procedure: Distance activities | Intervention Type: DEVICE; Name: Eye Patch; Assigned to Arm(s): Distance activities, Near activities | Intervention Type: PROCEDURE; Name: Near activities; Assigned to Arm(s): Near activities | Intervention Type: PROCEDURE; Name: Distance activities; Assigned to Arm(s): Distance activities
D: Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Patching, Procedure: Near activities | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine, Procedure: Near activities | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Patching; Assigned to Arm(s): Patching | Intervention Type: PROCEDURE; Name: Near activities; Assigned to Arm(s): Atropine, Patching

Answer: A